Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
8.78
-0.30 (-3.36%)
Jun 9, 2025, 4:00 PM - Market closed
Cullinan Therapeutics Employees
Cullinan Therapeutics had 111 employees as of December 31, 2024. The number of employees increased by 26 or 30.59% compared to the previous year.
Employees
111
Change (1Y)
26
Growth (1Y)
30.59%
Revenue / Employee
n/a
Profits / Employee
-$1,610,234
Market Cap
516.97M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 111 | 26 | 30.59% |
Dec 31, 2023 | 85 | 23 | 37.10% |
Dec 31, 2022 | 62 | 31 | 100.00% |
Dec 31, 2021 | 31 | 7 | 29.17% |
Dec 31, 2020 | 24 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
CGEM News
- 5 days ago - Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases - GlobeNewsWire
- 9 days ago - Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology - PRNewsWire
- 12 days ago - Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference - GlobeNewsWire
- 18 days ago - Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025 - GlobeNewsWire
- 4 weeks ago - Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 6 weeks ago - Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren's Disease in the United States - GlobeNewsWire
- 6 weeks ago - Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025 - GlobeNewsWire
- 7 weeks ago - Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis - GlobeNewsWire